Related Experiment Video
Updated: Jul 19, 2026
09:45
Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
Unsafe rear-end collision avoidance in Alzheimer's disease
Ergun Y Uc1, Matthew Rizzo, Steven W Anderson
1Division of Neuroergonomics, Department of Neurology, College of Medicice, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA. ergun-uc@uiowa.edu
Journal of the Neurological Sciences
|October 20, 2006
Summary
Drivers with Alzheimer's disease (AD) showed more unsafe driving behaviors, like abrupt braking, increasing rear-end collision risks. Cognitive and visual tests predicted these driving impairments, even in early stages.
Area of Science:
- Neuroscience
- Gerontology
- Traffic Safety
Background:
- Cognitive impairment, particularly in Alzheimer's disease (AD), significantly elevates the risk of vehicular crashes.
- Rear-end collisions (REC) represent a common and dangerous type of motor vehicle accident.
Purpose of the Study:
- To evaluate the ability of drivers with mild Alzheimer's disease (AD) to avoid rear-end collisions (REC) compared to elderly controls.
- To identify specific driving behaviors and cognitive factors associated with increased REC risk in drivers with AD.
Main Methods:
- A high-fidelity driving simulator was used to assess REC avoidance in 61 drivers with mild AD and 115 elderly controls.
- Participants encountered a lead vehicle suddenly stopping, with outcomes including REC or risky avoidance maneuvers recorded.
- Cognitive and visual tests, along with driving performance metrics, were analyzed for predictive value.
Main Results:
- 89% of drivers with AD experienced unsafe outcomes (REC or risky avoidance) versus 65% of controls (P=0.0007).
- Drivers with AD exhibited significantly more abrupt (70% vs. 37%, P<0.0001) and premature braking (66% vs. 45%, P=0.0115).
- Abrupt braking was linked to a higher likelihood of being struck from behind (P=0.0262); cognitive and visual test performance predicted unsafe outcomes.
Conclusions:
- Drivers with mild AD demonstrate impaired ability to respond to hazards that could lead to rear-end collisions.
- Specific cognitive deficits and visual perception issues predict unsafe driving outcomes in individuals with early-stage Alzheimer's disease.
- Driving simulation provides a valuable tool for assessing real-world driving risks associated with cognitive impairment.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.